In light of the growing armamentarium of complement-targeting molecules, including C5aR1 antagonists with excellent safety profile, we anticipate that our studies will provide important mechanistic information and preclinical data for clinical testing the hypothesis that inhibition of complement activation or signaling retards the progression of ADPKD. The gene discussed is C5AR1; the disease is autosomal dominant polycystic kidney disease.